Paul Mampilly Advises His Subscribers To Invest In Precision Medicine

Investment expert Paul Mampilly wrote a newsletter last year that encouraged readers to invest in precision medicine. In the newsletter, he said that precision medicine would explode quicker than expected. Paul Mampilly told his newsletter subscribers that they may be able to make up to $100,000 by investing $10,000 in his specific picks. Within a short time, one key company announced its plans to start three new precision-based trials.

Why Investors Listen To Paul Mampilly

While many people retire well after the age of 65 today, Paul Mampilly retired before the age of 45. He was able to retire because of his smart investments. When Amazon was a new company that many people were skeptical of, Paul Mampilly saw its growth potential and invested in it. He also made many other wise investments that positioned him as an expert.

In addition to his investment experience, Paul Mampilly worked for many years as a hedge fund manager. He managed the $6 billion Kinetics Asset Management fund, which saw average returns of 26 percent under his care. He grew that fund to a total of $25 billion. Paul Mampilly also managed funds for the Royal Bank of Scotland, Sears and a private bank in Switzerland. Although Paul Mampilly is known for making bold predictions, they are usually accurate. When the country faced a major financial crisis in 2008, Paul Mampilly earned $88 million from a $50 million investment. He did this as part of a competition to win a prestigious award from the Templeton Foundation. Paul Mampilly received the award in 2009.

The Future Of Precision Medicine

Paul Mampilly shares some of his basic investment tips for free through Banyan Hill Publishing’s website. The organization features advice from multiple investment experts who have proven success records, expertise in applied fields and the ability to make bold but accurate predictions. In a recent Banyan Hill publication, Paul Mampilly called precision medicine one of history’s biggest breakthroughs. Although medical students and some doctors are knowledgeable about certain types of precision medicine, other physicians who are too busy to keep up with trends are not familiar with it. According to Paul Mampilly, precision medicine will soon change treatment approaches for Parkinson’s disease, arthritis, cancer and many other diseases.

Today, the pharmaceutical industry mostly focuses on treating diseases or illnesses rather than curing them. Many treatments reduce symptoms or delay the progression of a disease. Using a standardized approach to treat common conditions is not optimal. With cancer, some companies that focus on precision treatments already analyze patients’ DNA and other specific factors to build unique profiles. By gathering this data and analyzing different treatment methods for people, medical scientists are finding patterns in treatment options and discovering which methods are best for certain people. For example, Tempus is a company that gathers such data and builds genomic profiles for cancer patients. To treat new patients, participating doctors access the database for information about treatments that were effective for other patients with the same type of tumor and similar genomic profiles.

As these types of systems continue to expand their databases, physicians will be able to refine treatment options even more. In the past, oncologists with limited information often recommended treatments based on overall success rates. Patients who had biological factors that made them less responsive to such treatments had no way of knowing their limitations before starting treatment. Harsh chemo cocktails and other ineffective treatments often left some patients too sick or too weak to continue with other options. Doctors will eventually be able to analyze a patient’s genomic profile first and suggest ideal treatments quickly. As treatments also continue to improve in their effectiveness, there will be more options for people with certain biological factors. Also, there will be more options for people with diseases other than cancer.

Leaders In Precision Medicine

Although one important company recently announced upcoming trials, there are other biotech companies that are working on promising innovations. Paul Mampilly has been studying these companies. In a recent Banyan Hill publication, he promised to reveal one of the best picks to his newsletter subscribers. Paul Mampilly publishes a newsletter called Profits Unlimited, which is accessible for a modest fee. His newsletter started out small and quickly grew to have thousands of subscribers. Today, Paul Mampilly has more than 90,000 subscribers for his Profits Unlimited newsletter.

Paul Mampilly is still legendary on Wall Street. He originally started as an assistant to a portfolio manager but quickly gained fame because of his consistency in smart picks. After Paul more than quadrupled the value of a massive hedge fund years later, the Templeton Foundation invited him to compete in its famous investment competition. Paul Mampilly proved his skills and consistency by making his investment grow significantly despite prices in all asset classes falling during that time. General prices for stocks, bonds and real estate fell. Although many wealthy individuals reaped the benefits of Paul’s insight and boldness in the past, he decided to help average Americans succeed.

After Paul Mampilly retired early, he shared his valuable investment advice in 2016 when he started Profits Unlimited. Today, he also publishes a newsletter called Extreme Fortunes with investment advice. He encourages Americans to utilize his tips and save for retirement to avoid having to work past the age of 65. Paul Mampilly has been featured on Bloomberg TV, Fox Business News, CNBC and other news outlets. In 2017, Paul Mampilly also launched a research service startup called True Momentum. When he attended SUNY in Albany, Paul Mampilly worked in a cafeteria. He said that he learned the value of hard work there. Today, he applies that work ethic to his research to help Americans make more profitable investment choices.